A Phase 1 interventional study of Clindamycin and Benzoyl Peroxide Gel 1.2%/3.75% and Onexton™ Gel in Acne Vulgaris, sponsored by Taro Pharmaceuticals USA. Completed. Open to participants aged 12 Years to 40 Years. Per ClinicalTrials.gov, last updated 2018-05-18.
Sponsored by Taro Pharmaceuticals USA (part of Sun Pharmaceutical Industries Limited) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies in Acne Vulgaris by Sun Pharmaceutical Industries Limited — none open to participants now, 1 under way, none of them phase 3. Acne Vulgaris · Sun Pharmaceutical Industries Limited.
Among the 30 studies in Acne Vulgaris by Sun Pharmaceutical Industries Limited, this one is the 13th largest by enrollment, is one of 4 that started in 2015, is one of 21 in phase 1, and was the 8th registered.
791 studies on the registry are indexed under Acne Vulgaris; 93 are open to participants now.
Browse Acne Vulgaris studies →None of the 30 studies in Acne Vulgaris by Sun Pharmaceutical Industries Limited is open now. The open studies under Acne Vulgaris, anywhere →
Of the 46 Acne Vulgaris studies recruiting now, 16 (35%) set no upper age limit and 29 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.
This study: 12 Years to 40 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 4 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 844 is above the median of 70 across 673 interventional studies indexed under Acne Vulgaris.
Median enrollment 727 across the 30 interventional studies. Of the 29 that completed or were terminated, 8 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Taro Pharmaceuticals USA, one of the names counted as Sun Pharmaceutical Industries Limited. Under that name alone:
Taro Pharmaceuticals USA is the lead sponsor of 71 studies on the registry; none are open to participants now.
Of its 19 completed or terminated interventional studies of FDA-regulated products, 1 (5%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 30 studies in Acne Vulgaris by Sun Pharmaceutical Industries Limited, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objectives of this study are to evaluate the therapeutic equivalence and safety.
The objectives of this study are to evaluate the therapeutic equivalence and safety of the test product Clindamycin and Benzoyl Peroxide Gel 1.2%/3.75% to the reference product Onexton™ Gel (Clindamycin and Benzoyl Peroxide Gel 1.2%/3.75%) in the treatment of acne vulgaris and to demonstrate the superiority of the efficacy of these test and reference products over the placebo control.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clindamycin and Benzoyl Peroxide Gel 1.2%/3.75% applied to the face once daily for 84 days.
Drug: Clindamycin and Benzoyl Peroxide Gel 1.2%/3.75%
Onexton™ Gel (Clindamycin and Benzoyl Peroxide Gel 1.2%/3.75%) applied to the face once daily for 84 days.
Drug: Onexton™ Gel
Placebo (vehicle of the test product) applied to the face once daily for 84 days.
Drug: Placebo
Clindamycin and Benzoyl Peroxide Gel 1.2%/3.75% (Taro Pharmaceuticals Inc.)
Also known as: Clindamycin, BPO
Onexton™ Gel (Clindamycin and Benzoyl Peroxide Gel 1.2%/3.75%) (Valeant Pharmaceuticals LLC)
Also known as: Clindamycin, BPO
Placebo (vehicle of the test product) (Taro Pharmaceuticals Inc.)
Also known as: Vehicle
Demonstration of Bioequivalence
Demonstration of Bioequivalence in percent change in inflammatory and non-inflammatory lesion counts
Time frame: Week 12
Clinical response of success
The proportion of subjects with a clinical response of success at week 12 defined as an Investigator's Global Assessment score that is at least 2 grades less than the baseline assessment.
Time frame: Week 12
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
The record gives a start of Apr 2015, a primary completion of Aug 2015 and a completion of Sep 2015. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.